Laboratory:Akiruno
- TOP
- gene-related test
- genetic tests for malignant tumor (solid tumor)
- Thyroid Cancer Oncomine DxTT Multi-2 Gene CDxFF
Laboratory:Akiruno
○Thyroid Cancer Oncomine DxTT Multi-2 Gene CDxFF
CODE:00W55 8
-
TEST NAME
SPECIMEN
REQUIREMENT
(mL) CONTAINER CAP COLOR STORE
TEMPERATURE
(STABILITY) TURNAROUND
TIME (DAY) METHODOLOGY REFERENCE RANGE
(UNIT) -
Thyroid Cancer Oncomine DxTT Multi-2 Gene CDxFF
tissue
100mg
ARR
6-11 Next Generation Sequencing (NGS)A method that uses a next-generation sequencer to simultaneously determine the base sequences of a huge number of DNA fragments.
COMMENT
The purpose of this study is to analyze RET gene mutation, RET fusion gene and BRAF gene V600E mutation in genomic DNA and RNA extracted from cancer tissue to assist determination of the indication of the drugs listed in the attached table for thyroid carcinoma and medullary thyroid carcinoma.
Acceptable days are Monday to Friday.
Please make sure that the material contains the tumor site before submitting it. Please avoid duplicate requests with other items. Since this test method is more susceptible to contamination, please handle the specimens with care when collecting them.
When requesting this test, please be sure to request the nucleic acid extraction item (item code No.0M961 2) at the same time.
●Notes
After collecting the specimen, please process it immediately. Please note that if the number of cells in the submitted specimen is low, the test may not be possible.
CONTAINER
ARR 旧容器記号 r A
滅菌ポリスピッツ
貯蔵方法:室温
supplementary information
対象遺伝子変異等と関連する医薬品および適応がん腫
遺伝子変異等 | がん腫 | 関連する医薬品 |
---|---|---|
RET融合遺伝子 | 甲状腺癌 | セルペルカチニブ |
BRAF遺伝子V600E変異 | エンコラフェニブ及びビニメチニブ | |
RET遺伝子変異 | 甲状腺髄様癌 | セルペルカチニブ |